JAZZ - Jazz Pharma acquires cancer program from Redx Pharma for up to $207M July, 10 2019 11:33 AM Jazz Pharmaceuticals plc Jazz Pharmaceuticals (JAZZ -0.8%) inks an agreement with British biotech Redx Pharma Plc to acquire its pan-RAF inhibitor program for the potential treatment of RAF- and RAS-mutant tumors.More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Read more ...